论文部分内容阅读
目的：观察抗肿瘤新药泰素（紫杉醇，Paclitaxel）加顺铂治疗晚期非小细胞肺癌（NSCLC）的疗效及毒性反应。方法：泰素180mg/m3静滴第1天，用泰素前给予抗过敏处理。顺铂25mg/m2静滴第2－4天.每三周重复，每例均完成二周期化疗。结果：14例晚期NSCLC病人中，部分缓解（PR）4例，稳定（NC）7例，进展（PD）3例。总有效率28．6％。初治有效率40％（2／5），复治有效率22％（2／9）。主要副作用是骨髓抑制，神径肌肉毒性也相当常见。结论：以泰素为主的联合方案治疗晚期NSCLC能取得一定疗效，对初治者有较好的缓解率。毒副作用可以耐受。
OBJECTIVE: To observe the efficacy and toxicity of antitumor drug paclitaxel plus cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Method: Paclitaxel 180 mg/m3 intravenous infusion on the first day, anti-allergic treatment was given before administration of Taxol. Cisplatin 25mg/m2 intravenous infusion on the second day of 2-4 days. Repeated every three weeks, each case completed two cycles of chemotherapy. Results: Of the 14 patients with advanced NSCLC, 4 were partial remission (PR), 7 were stable (NC), and 3 were progressive (PD). The total efficiency is 28.6%. The initial treatment efficiency is 40% (2/5), and the retreatment efficiency is 22% (2/9). The main side effect is myelosuppression. Diabetic muscle toxicity is also quite common. Conclusion: The combination of paclitaxel-based regimen for the treatment of advanced NSCLC can achieve a certain effect, and has a better remission rate for the initial treatment. The toxic side effects can be tolerated.